Study on effect of bevacizumab combined with chemotherapy on expression of serum EGFR and HER in patients with metastatic colorectal cancer
10.3969/j.issn.1671-8348.2017.33.018
- VernacularTitle:贝伐珠单抗联合化疗对转移性结直肠癌患者血清EGFR及HER表达的影响研究
- Author:
Lichun DENG
1
;
uaming H SHENG
;
Lei XI
;
Xiongwei LIU
;
Jie ZENG
;
Xiangming CAO
Author Information
1. 江苏省江阴市人民医院肿瘤科 214400
- Keywords:
receptor,epidermal growth factor;
bevacizumab;
metastatic colorectal cancer;
human epidermal grow th factor re-ceptor
- From:
Chongqing Medicine
2017;46(33):4659-4661
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of bevacizumab combined with chemotherapy on the expression of EGFR and HER in the patients with metastatic colorectal cancer .Methods Sixty patients with metastatic colorectal cancer treated in this hos-pital from January 2013 to October 2016 were selected and randomly divided into the experiment group (bevacizumab combined with FOLFOX-6 chemotherapy regimen) and control group (FOLFOX-6 chemotherapy regimen) 30 cases in each group .The curative effects were observed in the two groups .The levels of serum HER and EGFR were detected by enzyme-linked immunosorbent assay (ELISA) .Results The total effective rate after treatment in the experiment group was 53 .33% ,which in the control group was 33 .33% ,the difference was statistically significant (P< 0 .05) .After treatment ,the levels of serum HER and EGHR in the two groups were decreased to some extent ,moreover the experiment group had more decrease than the control group ,the difference be-tween the two groups was statistically significant (P<0 .05) .The occurrence rate of adverse reactions had no statistical difference between the two groups (P>0 .05) .Conclusion Bevacizumab combined with chemotherapy has good effect in the patients with metastatic colorectal cancer .
